Ivosidenib plus azacitidine for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, untreated AML (not previously treated, except limited temporary measures).
- Your leukemia has an IDH1 R132 gene mutation, confirmed by testing.
- You cannot safely receive intensive chemotherapy because of age (75+), limited activity (ECOG 2), or other serious health issues your doctor judges incompatible.
- Your liver and kidney function meet the trial’s lab requirements.
- If you could become pregnant, you must have a negative pregnancy test and use effective birth control during treatment and for at least 6 months after. If you have reproductive-partner risk, you must use effective birth control during treatment and for at least 3 months after.
- You are not currently dealing with certain exclusions like uncontrolled infections, recent major heart problems, uncontrolled high blood pressure, or swallowing/stomach problems that affect oral medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.